329 related articles for article (PubMed ID: 35724948)
21. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
22. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
23. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
24. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
26. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
[TBL] [Abstract][Full Text] [Related]
27. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
Kennedy VE; Perkins C; Reiter A; Jawhar M; Lübke J; Kluin-Nelemans HC; Shomali W; Langford C; Abuel J; Hermine O; Niedoszytko M; Gorska A; Mital A; Bonadonna P; Zanotti R; Tanasi I; Mattsson M; Hagglund H; Triggiani M; Yavuz AS; Panse J; Christen D; Heizmann M; Shoumariyeh K; Müller S; Elena C; Malcovati L; Fiorelli N; Wortmann F; Vucinic V; Brockow K; Fokoloros C; Papageorgiou SG; Breynaert C; Bullens D; Doubek M; Ilerhaus A; Angelova-Fischer I; Solomianyi O; Várkonyi J; Sabato V; Rüfer A; Schug TD; Hermans MAW; Fortina AB; Caroppo F; Bumbea H; Gulen T; Hartmann K; Elberink HO; Schwaab J; Arock M; Valent P; Sperr WR; Gotlib J
Blood Adv; 2023 May; 7(9):1713-1724. PubMed ID: 36094848
[TBL] [Abstract][Full Text] [Related]
28. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
29. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies.
Chantran Y; Valent P; Arock M
Immunol Allergy Clin North Am; 2023 Nov; 43(4):651-664. PubMed ID: 37758404
[TBL] [Abstract][Full Text] [Related]
30. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
Lübke J; Schwaab J; Naumann N; Horny HP; Weiß C; Metzgeroth G; Kreil S; Cross NCP; Sotlar K; Fabarius A; Hofmann WK; Valent P; Gotlib J; Jawhar M; Reiter A
J Clin Oncol; 2022 Jun; 40(16):1783-1794. PubMed ID: 35235417
[TBL] [Abstract][Full Text] [Related]
31. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
33. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
Akin C; Arock M; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
[TBL] [Abstract][Full Text] [Related]
35. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
Valent P; Akin C; Sperr WR; Horny HP; Arock M; Metcalfe DD; Galli SJ
Annu Rev Pathol; 2023 Jan; 18():361-386. PubMed ID: 36270293
[TBL] [Abstract][Full Text] [Related]
36. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
Tashi T; Deininger MW
Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
[TBL] [Abstract][Full Text] [Related]
37. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
[TBL] [Abstract][Full Text] [Related]
39. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis.
Berezowska S; Flaig MJ; Ruëff F; Walz C; Haferlach T; Krokowski M; Kerler R; Petat-Dutter K; Horny HP; Sotlar K
Mod Pathol; 2014 Jan; 27(1):19-29. PubMed ID: 23807778
[TBL] [Abstract][Full Text] [Related]
40. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
